Current status of immunotherapy and targeted therapy for intrahepatic cholangiocarcinoma
10.3969/j.issn.1000-8179.2019.13.317
- VernacularTitle:肝内胆管细胞癌免疫治疗和靶向治疗研究现状*
- Author:
Heyue ZHANG
1
;
Tianqiang JIN
;
Chaoliu DAI
;
Feng XU
Author Information
1. 中国医科大学附属盛京医院肝胆脾外科(沈阳市110004)
- Keywords:
intrahepatic cholangiocarcinoma (ICC);
immunotherapy;
targeted therapy
- From:
Chinese Journal of Clinical Oncology
2019;46(13):694-699
- CountryChina
- Language:Chinese
-
Abstract:
Intrahepatic cholangiocarcinoma (ICC) is the second most frequently occurring primary liver cancer. It has been reported that the causes of late diagnosis of ICC are a high degree of malignancy, early metastasis, and diffusion. Most patients visit the hospital because of jaundice or discomfort due to the surrounding compression. ICC commonly recurs after resection, and chemotherapy is not sensitive. Therefore, patients have a poor prognosis and a low survival rate. Currently, a multidisciplinary approach based on surgery is recommended for ICC patients who can undergo surgical excision, and local treatment combined with chemotherapy is the main com-prehensive treatment for patients with advanced ICC who cannot undergo surgical resection. In recent years, it has been found that immunotherapy can involve the autoimmune system to remove tumor cells, and molecular-targeted therapy can kill tumor cells by in-hibiting cell membrane surface molecules that promote tumorigenesis and development. At present, these two treatment modalities have become the research focus of ICC therapy, and progress has been made. The research status is reviewed in this paper.
